Document Detail

Anti-inflammatory activity of a pteridine derivative (4AZA2096) alleviates TNBS-induced colitis in mice.
MedLine Citation:
PMID:  16881868     Owner:  NLM     Status:  MEDLINE    
Elevated production of tumor necrosis factor (TNF) plays a central role in the pathogenesis of many inflammatory diseases, such as rheumatoid arthritis and Crohn's disease. Naturally occurring pteridine analogs have been reported to have potent immunomodulatory activity, especially on TNF production. The aim of this study is to identify small molecule TNF inhibitiors derived from pteridine and to prove their in vivo efficacy in an inflammatory model. A focused chemical library based on the pteridine scaffold was screened in vitro on lipopolysaccharide (LPS)-induced TNF production in peripheral blood mononuclear cells (PBMC). One synthetic pteridine analog (4AZA2096), shown to have strong inhibitory activity, was selected and tested for its efficacy to treat trinitrobenzenesulfonate (TNBS)-induced colitis in mice, a model of Crohn's disease. Colitis was induced by rectal administration of 1 mg TNBS in 50% ethanol after presensitization via the skin. The synthetic pteridine analog 4AZA2096 was shown to potently inhibit LPS-induced TNF production in vitro. Colitic mice treated with 4AZA2096 orally (20 mg/kg/day) recovered more rapidly and, histologically, had a reduction of inflammatory lesions, less edema, a reduction of goblet cell loss, and reduced wall thickness. Cell infiltration in the colon, especially infiltration of neutrophils, as shown by myeloperoxidase (MPO) activity, was reduced in 4AZA2096-treated animals. Intralesional TNF production was lower in mice of the treated groups, whereas interleukin-18 (IL-18) and interferon-gamma (IFN-gamma) mRNA were not affected. Treatment had no effect on anti-TNBS antibody production, arguing against generalized immunosuppression. In conclusion, we identified a pteridine derivative, 4AZA2096, with strong inhibitory activity on TNF production and a remission- inducing effect in TNBS colitis, supporting further preclinical and clinical development of this novel TNF inhibitor for treatment of inflammatory diseases.
Chong Shen; Ellen Dillissen; Ahmad Kasran; Yuan Lin; Gavin Clydesdale; Ilse Sienaert; Steven De Jonghe; Ling-Jie Gao; Karel Geboes; Louis Boon; Paul Rutgeerts; Jan L Ceuppens
Related Documents :
19327358 - Prohibitin is a novel regulator of antioxidant response that attenuates colonic inflamm...
18931948 - Gastroprotective effect of nicorandil in indomethacin and alcohol-induced acute ulcers.
15302898 - Erythropoietin reduces the development of experimental inflammatory bowel disease.
6302178 - Control of systemic spread of candida albicans with ketoconazole in the stomachs of mic...
9479568 - Canine x-linked severe combined immunodeficiency. a model for investigating the require...
23382928 - Il-18 induces airway hyperresponsiveness and pulmonary inflammation via cd4(+) t cell a...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research     Volume:  26     ISSN:  1079-9907     ISO Abbreviation:  J. Interferon Cytokine Res.     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-08-02     Completed Date:  2006-09-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9507088     Medline TA:  J Interferon Cytokine Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  575-82     Citation Subset:  IM    
Laboratory of Experimental Immunology, Faculty of Medicine, Katholieke Universiteit Leuven, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Inflammatory Agents / pharmacology,  therapeutic use*
Antibodies / blood
Cells, Cultured
Colitis / chemically induced,  drug therapy*,  pathology
Colon / enzymology
Cytokines / genetics,  metabolism
Interleukin-1 / biosynthesis
Leukocytes, Mononuclear / drug effects,  immunology
Lipopolysaccharides / antagonists & inhibitors
Mice, Inbred C57BL
Peroxidase / metabolism
Pteridines / pharmacology,  therapeutic use*
RNA, Messenger / metabolism
T-Lymphocytes / immunology
Trinitrobenzenesulfonic Acid / immunology
Tumor Necrosis Factor-alpha / antagonists & inhibitors*,  biosynthesis
Reg. No./Substance:
0/4AZA2096; 0/Anti-Inflammatory Agents; 0/Antibodies; 0/Cytokines; 0/Interleukin-1; 0/Lipopolysaccharides; 0/Pteridines; 0/RNA, Messenger; 0/Tumor Necrosis Factor-alpha; 2508-19-2/Trinitrobenzenesulfonic Acid; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Influence of IFN- alpha and IFN- gamma on lymphangiogenesis.
Next Document:  Ovine plasma prion protein levels show genotypic variation detected by C-terminal epitopes not expos...